5.45p
-0.91%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Renalytix
Its shares trade on LSE under the ticker RENX.L. It has been listed since 6 November 2018. In the fiscal year to 30 June 2026, it reported revenue of $3.0m and a net loss of $14.2m. At that date it held total assets of $4.6m and shareholders' equity of −$6.3m.
Renalytix Plc manufactures medical devices and equipment. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Its diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. KidneyIntelX is a bioprognostic methodology. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations, and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Technology
- Listed since
- 6 Nov 2018
- Employees
- 80
- Website
- renalytix.com ↗
Leadership
Pay as last reported
- James Renwick McCullough, MBAChief Executive Officer & Director, since 2018
- Thomas H. McLain, MBA. CPAPresident & Chief Commercial Officer, since 2019
- James O. Sterling, MBAChief Financial Officer, since 2018
- Michael J. Donovan, MD, PhDChief Medical Officer, since 2018
- Fergus FlemingDirector & Chief Technology Officer, since 2018
- Jean M. CasnerChief Human Resources Officer & Senior VP, since 2022
- Joseph HutsonVice President-Quality & Regulatory, since 2022
- Jed D. FulkVice President-Sales & Government Accounts, since 2022
- Andria Parks-HerreraVice President-Marketing, since 2022
- Salim HamirSecretary
- Sally Bowden, MBAHead-Regulatory Affairs, since 2018
- Christopher Harwood Bernard MillsNon-Executive Chairman
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Renalytix PLC focuses on optimizing clinical management of kidney disease with its diagnostic platform KidneyIntelX.
- The company has a proprietary algorithm that combines blood-based biomarkers, genetics, and electronic health record data.
- KidneyIntelX is designed to scale across various kidney disease conditions beyond diabetic kidney disease.
Weaknesses
- The company is a small entity with only 80 employees.
- Renalytix PLC is a publicly traded company with a relatively recent IPO in 2018.
- The firm's business model relies on a single diagnostic platform, KidneyIntelX.
Opportunities
- KidneyIntelX is being evaluated for new indications in chronic kidney disease and cardio-renal disease.
- The platform has potential for expansion into diverse populations and coronavirus disease-related kidney disease.
- Renalytix PLC can leverage its proprietary algorithm to address unmet needs in kidney disease management.
Threats
- The company's reliance on a single diagnostic platform poses a significant business risk.
- Renalytix PLC operates in a highly competitive health care sector with established players.
- The firm's financial performance may be impacted by the slow adoption of new medical technologies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.